Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products
Jeffery J. Auletta(Nationwide Children's Hospital), Steven M. Devine(National Marrow Donor Program), Sade T. Fridy-Chesser(National Marrow Donor Program), Gretta L. Stritesky(National Marrow Donor Program), Jen L. Novakovich(National Marrow Donor Program), Jeni Newman(National Marrow Donor Program), Karl Hailperin(National Marrow Donor Program)
Cited by 27
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
|Journal of Clinical Oncology|2019|441